SEC Form 4 · accession 0002153366-26-000006
Electra Therapeutics, Inc. · ETRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Graham Parry
Officer — Chief Scientific Officer
Period of report
Sep 21, 2026
Accepted (ET)
Sep 21, 2026 · 6:17 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002088082
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Sep 21, 2026 | C | 85,504 | — | A | 85,504 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF1,F2 | — | Sep 21, 2026 | C | 85,504 | D | — | — | Common Stock | 85,504 | 0 | D |
Explanation of responses
- F17,125 of the shares ("Restricted Shares") shall be subject to vesting as follows: 1/4th of the Restricted Shares shall vest monthly commencing from September 2, 2026.
- F2Each share of Series A Convertible Preferred Stock (the "Preferred Stock") converted automatically into 1 share of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock had no expiration date.